Advances and Challenges of Stem-Cell-Based Therapy for CNS Disorders
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 558
Special Issue Editors
Interests: mesenchymal stem cells; secretome; Parkinson’s disease; induced pluripotent stem cells; neurodegeneration
Interests: spinal cord injury; biomaterials; pharmacology; regeneration; immunomodulation
Special Issues, Collections and Topics in MDPI journals
2. ICVS/3B's–PT Government Associate Laboratory, Braga/Guimarães, Portugal
Interests: regenerative medicine; stem cells; secretome; biomaterials; spinal cord injury; Parkinson's disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. Due to the central nervous system’s (CNS) limited capacity to spontaneously regenerate, few therapeutic approaches are available for CNS disorders, which can either be caused by disease or injury. Therefore, regenerative medicine strategies are crucial in halting disease progression and promoting tissue regeneration.
In recent decades, stem cells have been put forward as a promising tool for CNS regenerative medicine. The advent of cell reprogramming has allowed the generation of induced pluripotent stem cells (iPSCs), overcoming the ethical and legal issues associated with the use of human embryonic stem cells. Since then, iPSCs have been established as one of the most relevant cell sources for the generation of tissue-specific cell types for cell replacement therapies.
Multipotent stem cells, such as mesenchymal stem cells, have also been shown to present regenerative effects, mostly attributed to the secretion of the bioactive factor (i.e., their secretome) rather than their integration in host tissue.
This Special Issue aims to compile experimental studies and reviews addressing the effects of pluripotent and multipotent stem cells for CNS disorders in preclinical models, and/or discussing the challenges of their use in future clinical applications.
Dr. Ana Marote
Dr. Nuno A. Silva
Dr. António Salgado
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegenerative disorders
- neurotrauma
- induced pluripotent stem cells
- mesenchymal stem cells
- neural stem cells
- cell transplantation strategies
- secretome-based therapies
- good manufacturing practice
- regenerative medicine
- cell proliferation and differentiation
